Canada Peptides CJC-1295

Description

• Manufacturer: Canada Peptides
• Packing: 2mg in vial
• Active ingredient: growth hormone-releasing factor (GRF or GHRF) or somatocrinin
• Office: Canada
• Production facilities: China

History of Canada Peptides CJC-1295

Biotechnology company ConjuChem from Canada created the CJC-1295 DAC back in 2005, but its widespread use in strength sports began 5-6 years later. It was then that some third-party companies, together with Chinese manufacturers, gained access to the technology for the production of the drug.

Canada Peptides CJC-1295 is a peptide hormone, also known as GHRH, designed to stimulate the production of growth hormone. CJC 1295 directly affects the pituitary gland, which leads to an increase in the synthesis of growth hormone in the human body.

Canada Peptides CJC-1295 has been successfully used in the west for a long time. At first it was used in combination with other peptides at the end of the steroid cycle to enhance the anabolic effect, but now CJC 1295 (you can buy it in our store) is in direct competition with many anabolic steroids and is absolutely safe and legal drug. The half-life of the peptide is 30 minutes, which is considered a pretty good indicator. Due to its long half-life and stability in effects, CJC 1295 is becoming increasingly popular.

A number of clinical trials have shown that even a single administration of this peptide causes a significant increase in growth hormone levels.

In the course of endocrinological studies, it was found that after a single injection of CJC-1295, there is an increase in the content of growth hormone in the blood plasma by 2-10 times with a duration of 6 days, as well as an increase in the concentration of IGF-1 by 1.5-3 times with a duration of 9- 11 days. These numbers are truly impressive!

For anabolic purposes, several injections per day (1-3 injections) are usually recommended, but for anti-aging purposes, just one injection per day, at bedtime, is enough. CJC-1295 is often taken in conjunction with GHRP-6 for maximum effect. using these peptides together greatly increases the amount of growth hormone released.

Joint action (synegyrism) GHRH + GHRP

It is well known that the concurrent use of Growth Releasing Hormone (GHRH – drugs such as CJC-1295 and mod GRF 1-29) and Growth Releasing Peptide (GHRP-6, GHRP-2, Hexarelin or Ipamorelin) results in synergistic GH release. In other words, if GHRH contributes GH amount quantified as number 2 and GHRPs contributes GH amount quantified as number 4, the total GH output is not cumulative (ie 2 + 4 = 6). Rather, the whole is greater than the sum of the parts, so 2 + 4 = 10.